NCT07476326 2026-03-17
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Biocon Limited
Phase 1 Not yet recruiting
Biocon Limited
Bristol-Myers Squibb
Boehringer Ingelheim
Merck Sharp & Dohme LLC
Pfizer
CatalYm GmbH